Allergy and Asthma Patients Flock to Emergency Rooms

The sneezing, watery eyes and runny noses from seasonal allergies are poised to land more people in the emergency room as temperatures rise, researchers have found.

In a study published online yesterday in GeoHealth, scientists reported that warmer winters resulting from climate change will lead to more intense pollen from oak trees, spelling more misery for allergy sufferers.

We believe that this is a health risk that has been underappreciated and is likely worsening, said lead author Susan Anenberg, an environmental scientist at Environmental Health Analytics LLC, a health research and consulting firm.

Several previous studies have shown that allergy seasons are continually getting worse as pollen gradually emerges earlier each year with greater vigor and longer duration (Climatewire, Aug. 25, 2016).

Increased carbon dioxide levels around plants like ragweed also leads to greater pollen production. For allergy sufferers, this pollen can trigger an immune response ranging from mild symptoms like headaches to severe problems like difficulty breathing.

Anenberg and her team sought to quantify the impact of this alarming allergy accrual.

The researchers looked at emergency room visits related to asthma, a common allergy complication, stemming from exposure to pollen from oak trees. This already leads to more than 20,000 emergency room trips in the United States each year, mostly for children younger than 18, with damages estimated at $10.4 million.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million